chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 25.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Genital herpes
Clinical narrative: Recurrent gentian herpes outbreak;This is a spontaneous report from a contactable consumer, the patient. A 25-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Apr2021 at 11:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included ethinylestradiol, norgestimate (TRINESSA LO) from an unknown date for birth control, spironolactone (MANUFACTURER UNKNOWN) from an unknown date for an unspecified indication. It was unknown if the patient was pregnant. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 15:00, the patient experienced recurrent gentian herpes outbreak. The event resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the event. The clinical outcome of the event Recurrent gentian herpes outbreak was resolving.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 50.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Rash, Rash pruritic, Rash vesicular
Clinical narrative: Bicep and ear rashes have small blisters; Persistently itchy rash on left inner bicep, top of right ear.; Matchbook-sized patch on right waistline; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 06Apr2021 at 11:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included rosacea on face (treated successfully with daily metronidazole) and chickenpox. The patient had no allergies to medications, food, or other products. Concomitant medication included metronidazole (MANUFACTURER UNKNOWN) 0.75 (unspecified unit) topical daily for rosacea from an unknown start date. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 08Apr2021 at 08:00, the patient experienced bicep and ear rashes had small blisters, persistently itchy rash on left inner bicep, top of right ear and matchbook-sized patch on right waistline. It was reported that began 48 hrs after vaccination, started as small defined points, then growing and appearance similar to shingles. The patient had not been vaccinated for shingles. She had chicken pox as a child. It was reported that the events did not result in doctor/other health care professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of bicep and ear rashes had small blisters, persistently itchy rash on left inner bicep, top of right ear and matchbook-sized patch on right waistline was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Headache, Pain in extremity, Pruritus, Pyrexia
Clinical narrative: Arm sore; Headache; Felt wiped out; Fever of 100.6 -101.0; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the right arm on 31Mar2021 at 16:15 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 in Dec2020. Patient had known penicillin allergy and allergy to AVELOX. Concomitant medications included naproxen sodium (ALEVE), colecalciferol (VITAMIN D3), ascorbic acid (VITAMIN C) and sambucus nigra (ELDERBERRY) all for an unknown indication from an unknown date. Prior to the vaccination, the patient was diagnosed with COVID-19 in Dec2020. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient had first dose of Pfizer and did not have adverse side effects not even much of a sore arm for almost 2 days. On 02Apr2021 at 14:15, the patient experienced fever of 100.6 -101.0 (units unspecified) which began 46 hours after being vaccinated and lasted about 12 hours. On 03Apr2021, the following day, she had no fever but suddenly her arm was sore, she had a headache, and felt wiped out until about 18:00. Later that evening, she was fine. She was surprised that her side effects were delayed for so long. No therapeutic measures were taken as a result of the adverse events. The events did not result in doctor or other healthcare professional office or clinic visit, emergency room or department or urgent care. The clinical outcome of the event fever of 100.6 -101.0, arm sore, headache and felt wiped out was recovered on 03Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Body temperature, Headache, Pain in extremity, Pyrexia
Clinical narrative: Arm sore; Headache; Felt wiped out; Fever of 100.6 -101.0; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the right arm on 31Mar2021 at 16:15 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 in Dec2020. Patient had known penicillin allergy and allergy to AVELOX. Concomitant medications included naproxen sodium (ALEVE), colecalciferol (VITAMIN D3), ascorbic acid (VITAMIN C) and sambucus nigra (ELDERBERRY) all for an unknown indication from an unknown date. Prior to the vaccination, the patient was diagnosed with COVID-19 in Dec2020. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient had first dose of Pfizer and did not have adverse side effects not even much of a sore arm for almost 2 days. On 02Apr2021 at 14:15, the patient experienced fever of 100.6 -101.0 (units unspecified) which began 46 hours after being vaccinated and lasted about 12 hours. On 03Apr2021, the following day, she had no fever but suddenly her arm was sore, she had a headache, and felt wiped out until about 18:00. Later that evening, she was fine. She was surprised that her side effects were delayed for so long. No therapeutic measures were taken as a result of the adverse events. The events did not result in doctor or other healthcare professional office or clinic visit, emergency room or department or urgent care. The clinical outcome of the event fever of 100.6 -101.0, arm sore, headache and felt wiped out was recovered on 03Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Arthralgia, Chills, Dizziness, Fatigue, Injection site discomfort
Clinical narrative: This is a spontaneous report from a contactable consumer (patient). A 40-year-old (non-pregnant) female patient received the second dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# ER8737), at the age of 40, via an unspecified route of administration, left arm, on Apr 8, 2021, single dose, for COVID-19 immunisation. Medical history included osteoarthritis of lumbar spine and chronic low-back pain. Prior to the vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient has not tested for COVID-19. The patient did not receive any medication within two weeks of vaccination. The patient has allergies to nickel, amoxicillin and wellbutrin. The patient previously received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# ER2613), at the age of 40, via an unspecified route of administration, left arm, on Mar 18, 2021, at 15:15, single dose, for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On Apr 8, 2021, at 15:30, patient experienced fatigue, body aches, muscle pain, joint pain, dizziness, brain fog and swollen lymph nodes. The patient reported the symptom onset was within 6-8 hours after the second dose. She fully recovered within 72 hours. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures taken as a result of the events (body aches, muscle pain, joint pain and swollen lymph nodes) included treatment with ibuprofen 800mg prn. Therapeutic measures were not taken for fatigue, dizziness and brain fog. The clinical outcome of fatigue, body aches, muscle pain, joint pain, dizziness, brain fog and swollen lymph nodes all resolved on Apr 11, 2021, at 15:30. No follow-up attempts needed. No further information expected.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Lymphadenopathy, Myalgia, Pain
Clinical narrative: This is a spontaneous report from a contactable consumer (patient). A 40-year-old (non-pregnant) female patient received the second dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# ER8737), at the age of 40, via an unspecified route of administration, left arm, on Apr 8, 2021, single dose, for COVID-19 immunisation. Medical history included osteoarthritis of lumbar spine and chronic low-back pain. Prior to the vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient has not tested for COVID-19. The patient did not receive any medication within two weeks of vaccination. The patient has allergies to nickel, amoxicillin and wellbutrin. The patient previously received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# ER2613), at the age of 40, via an unspecified route of administration, left arm, on Mar 18, 2021, at 15:15, single dose, for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On Apr 8, 2021, at 15:30, patient experienced fatigue, body aches, muscle pain, joint pain, dizziness, brain fog and swollen lymph nodes. The patient reported the symptom onset was within 6-8 hours after the second dose. She fully recovered within 72 hours. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures taken as a result of the events (body aches, muscle pain, joint pain and swollen lymph nodes) included treatment with ibuprofen 800mg prn. Therapeutic measures were not taken for fatigue, dizziness and brain fog. The clinical outcome of fatigue, body aches, muscle pain, joint pain, dizziness, brain fog and swollen lymph nodes all resolved on Apr 11, 2021, at 15:30. No follow-up attempts needed. No further information expected.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Arthralgia, Dizziness, Fatigue, Feeling abnormal, Lymphadenopathy
Clinical narrative: This is a spontaneous report from a contactable consumer (patient). A 40-year-old (non-pregnant) female patient received the second dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# ER8737), at the age of 40, via an unspecified route of administration, left arm, on Apr 8, 2021, single dose, for COVID-19 immunisation. Medical history included osteoarthritis of lumbar spine and chronic low-back pain. Prior to the vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient has not tested for COVID-19. The patient did not receive any medication within two weeks of vaccination. The patient has allergies to nickel, amoxicillin and wellbutrin. The patient previously received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# ER2613), at the age of 40, via an unspecified route of administration, left arm, on Mar 18, 2021, at 15:15, single dose, for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On Apr 8, 2021, at 15:30, patient experienced fatigue, body aches, muscle pain, joint pain, dizziness, brain fog and swollen lymph nodes. The patient reported the symptom onset was within 6-8 hours after the second dose. She fully recovered within 72 hours. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures taken as a result of the events (body aches, muscle pain, joint pain and swollen lymph nodes) included treatment with ibuprofen 800mg prn. Therapeutic measures were not taken for fatigue, dizziness and brain fog. The clinical outcome of fatigue, body aches, muscle pain, joint pain, dizziness, brain fog and swollen lymph nodes all resolved on Apr 11, 2021, at 15:30. No follow-up attempts needed. No further information expected.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Myalgia, Pain
Clinical narrative: This is a spontaneous report from a contactable consumer (patient). A 40-year-old (non-pregnant) female patient received the second dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# ER8737), at the age of 40, via an unspecified route of administration, left arm, on Apr 8, 2021, single dose, for COVID-19 immunisation. Medical history included osteoarthritis of lumbar spine and chronic low-back pain. Prior to the vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient has not tested for COVID-19. The patient did not receive any medication within two weeks of vaccination. The patient has allergies to nickel, amoxicillin and wellbutrin. The patient previously received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# ER2613), at the age of 40, via an unspecified route of administration, left arm, on Mar 18, 2021, at 15:15, single dose, for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On Apr 8, 2021, at 15:30, patient experienced fatigue, body aches, muscle pain, joint pain, dizziness, brain fog and swollen lymph nodes. The patient reported the symptom onset was within 6-8 hours after the second dose. She fully recovered within 72 hours. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures taken as a result of the events (body aches, muscle pain, joint pain and swollen lymph nodes) included treatment with ibuprofen 800mg prn. Therapeutic measures were not taken for fatigue, dizziness and brain fog. The clinical outcome of fatigue, body aches, muscle pain, joint pain, dizziness, brain fog and swollen lymph nodes all resolved on Apr 11, 2021, at 15:30. No follow-up attempts needed. No further information expected.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chills, Diarrhoea, Headache, Nausea, Pain
Clinical narrative: Vomiting; bodyaches; headache; cough; nauseous; diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received a first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in left arm on 08Apr2021 at 16:00 as a single dose for COVID-19 immunisation. Medical history included allergy to sulfa. Concomitant medication included venlafaxine hydrochloride (EFEXOR) 150 mg for an unknown indication and from an unknown start date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 09Apr2021 at 19:00, the patient experienced vomiting, body aches, headache, cough, nauseous and diarrhea. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. No therapeutic measures were taken as the result of adverse event. The clinical outcome of the events vomiting, body aches, headache, cough, nauseous and diarrhea were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, Vomiting
Clinical narrative: Vomiting; bodyaches; headache; cough; nauseous; diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received a first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in left arm on 08Apr2021 at 16:00 as a single dose for COVID-19 immunisation. Medical history included allergy to sulfa. Concomitant medication included venlafaxine hydrochloride (EFEXOR) 150 mg for an unknown indication and from an unknown start date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 09Apr2021 at 19:00, the patient experienced vomiting, body aches, headache, cough, nauseous and diarrhea. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. No therapeutic measures were taken as the result of adverse event. The clinical outcome of the events vomiting, body aches, headache, cough, nauseous and diarrhea were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Cough, Diarrhoea, Headache, Nausea, Pain
Clinical narrative: Vomiting; bodyaches; headache; cough; nauseous; diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received a first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in left arm on 08Apr2021 at 16:00 as a single dose for COVID-19 immunisation. Medical history included allergy to sulfa. Concomitant medication included venlafaxine hydrochloride (EFEXOR) 150 mg for an unknown indication and from an unknown start date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 09Apr2021 at 19:00, the patient experienced vomiting, body aches, headache, cough, nauseous and diarrhea. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. No therapeutic measures were taken as the result of adverse event. The clinical outcome of the events vomiting, body aches, headache, cough, nauseous and diarrhea were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Vomiting
Clinical narrative: Vomiting; bodyaches; headache; cough; nauseous; diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received a first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in left arm on 08Apr2021 at 16:00 as a single dose for COVID-19 immunisation. Medical history included allergy to sulfa. Concomitant medication included venlafaxine hydrochloride (EFEXOR) 150 mg for an unknown indication and from an unknown start date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 09Apr2021 at 19:00, the patient experienced vomiting, body aches, headache, cough, nauseous and diarrhea. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. No therapeutic measures were taken as the result of adverse event. The clinical outcome of the events vomiting, body aches, headache, cough, nauseous and diarrhea were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 73.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Feeling hot, Hypoaesthesia, Paraesthesia, Swelling
Clinical narrative: Left wrist became very hot,; Left wrist became swollen; Left wrist become painful; 4th and 5th fingers numb; 4th and 5th fingers tingly; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP8730) via an unspecified route of administration in the left arm on 27Mar2021 at 11:00 (at the age of 73-years-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid arthritis, Sjogren's and Raynaud's syndrome. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included methotrexate (MANUFACTURER UNKNOWN), folic acid (MANUFACTURER UNKNOWN), amlodipine (MANUFACTURER UNKNOWN) and ferrous sulfate (MANUFACTURER UNKNOWN); all for unknown indications from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 09:00,two days after 2nd vaccine the patient's left wrist become very hot, swollen, painful, 4thand 5th fingers numb and tingly. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with prednisone (MANUFACTURER UNKNOWN), naprosyn (MANUFACTURER UNKNOWN), and wrist splint. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events of left wrist become very hot, swollen, painful, 4thand 5th fingers numb and tingly was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 73.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Feeling hot, Hypoaesthesia, Joint swelling, Paraesthesia
Clinical narrative: Left wrist became very hot,; Left wrist became swollen; Left wrist become painful; 4th and 5th fingers numb; 4th and 5th fingers tingly; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP8730) via an unspecified route of administration in the left arm on 27Mar2021 at 11:00 (at the age of 73-years-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid arthritis, Sjogren's and Raynaud's syndrome. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included methotrexate (MANUFACTURER UNKNOWN), folic acid (MANUFACTURER UNKNOWN), amlodipine (MANUFACTURER UNKNOWN) and ferrous sulfate (MANUFACTURER UNKNOWN); all for unknown indications from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 09:00,two days after 2nd vaccine the patient's left wrist become very hot, swollen, painful, 4thand 5th fingers numb and tingly. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with prednisone (MANUFACTURER UNKNOWN), naprosyn (MANUFACTURER UNKNOWN), and wrist splint. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events of left wrist become very hot, swollen, painful, 4thand 5th fingers numb and tingly was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Supraventricular tachycardia
Clinical narrative: heart rate when up to 194 bpm; body aches; This is a spontaneous report from a contactable consumer (patient). This 47-year-old female patient received dose 1 of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number ER8729) via an unspecified route of administration on 12Apr2021 at 10:00 (at the age of 47-years-old) as a single dose in the left arm for COVID-19 immunization. Medical history was none. The patient was not pregnant at the time of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the vaccine. The patient was not diagnosed with COVID-19 prior to the vaccine. The patient did not take any concomitant medications. The patient had no known allergies. On 12Apr2021 at 10:00 the patient experienced heart rate went up to 194 beats per minute (BPM) and body aches. The patient visited an emergency room/department or urgent care as a result of the events. The patient received treatment with "4 baby" paracetamol (TYLENOL), oxygen, and an epinephrine (ADRENALINE) shot. The outcomes of heart rate went up and body aches were unknown. It was also reported that since the vaccination the patient had not been tested for COVID-19.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Heart rate increased
Clinical narrative: heart rate when up to 194 bpm; body aches; This is a spontaneous report from a contactable consumer (patient). This 47-year-old female patient received dose 1 of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number ER8729) via an unspecified route of administration on 12Apr2021 at 10:00 (at the age of 47-years-old) as a single dose in the left arm for COVID-19 immunization. Medical history was none. The patient was not pregnant at the time of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the vaccine. The patient was not diagnosed with COVID-19 prior to the vaccine. The patient did not take any concomitant medications. The patient had no known allergies. On 12Apr2021 at 10:00 the patient experienced heart rate went up to 194 beats per minute (BPM) and body aches. The patient visited an emergency room/department or urgent care as a result of the events. The patient received treatment with "4 baby" paracetamol (TYLENOL), oxygen, and an epinephrine (ADRENALINE) shot. The outcomes of heart rate went up and body aches were unknown. It was also reported that since the vaccination the patient had not been tested for COVID-19.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Heart rate, Heart rate increased, Pain
Clinical narrative: heart rate when up to 194 bpm; body aches; This is a spontaneous report from a contactable consumer (patient). This 47-year-old female patient received dose 1 of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number ER8729) via an unspecified route of administration on 12Apr2021 at 10:00 (at the age of 47-years-old) as a single dose in the left arm for COVID-19 immunization. Medical history was none. The patient was not pregnant at the time of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the vaccine. The patient was not diagnosed with COVID-19 prior to the vaccine. The patient did not take any concomitant medications. The patient had no known allergies. On 12Apr2021 at 10:00 the patient experienced heart rate went up to 194 beats per minute (BPM) and body aches. The patient visited an emergency room/department or urgent care as a result of the events. The patient received treatment with "4 baby" paracetamol (TYLENOL), oxygen, and an epinephrine (ADRENALINE) shot. The outcomes of heart rate went up and body aches were unknown. It was also reported that since the vaccination the patient had not been tested for COVID-19.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal distension, Abdominal pain upper, Headache, Oropharyngeal pain, Pyrexia
Clinical narrative: Started with lymphnodes, fever for 5 days, severe stomach bloating, now a rash; Started with lymphnodes, fever for 5 days, severe stomach bloating, now a rash; Started with lymphnodes, fever for 5 days, severe stomach bloating, now a rash; Started with lymphnodes, fever for 5 days, severe stomach bloating, now a rash; This is a spontaneous report from a contactable other healthcare professional, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 31Mar2021 at 12:30 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included pain knee (reported as Chronic pain right knee) and factor v deficiency (reported as factor v).The patient previously had avocado and experienced fruit allergy to avocado. The patient had latex allergy. The patient previously had received antibiotics and experienced allergy to antibiotic. Concomitant medications taken within two weeks of vaccination included paracetamol, oxycodone hydrochloride (PERCOCET), buspirone (BUSPERONE) and escitalopram oxalate (LEXIPRO), all from unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 at 11:00, the patient started with lymphnodes, fever for five days, severe stomach bloating, and a rash from an unknown date in Apr2021. The events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the events. The clinical outcome of the event fever for five days was resolved on 05Apr2021. The clinical outcome of the events started with lymphnodes, severe stomach bloating, a rash was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Rash
Clinical narrative: Started with lymphnodes, fever for 5 days, severe stomach bloating, now a rash; Started with lymphnodes, fever for 5 days, severe stomach bloating, now a rash; Started with lymphnodes, fever for 5 days, severe stomach bloating, now a rash; Started with lymphnodes, fever for 5 days, severe stomach bloating, now a rash; This is a spontaneous report from a contactable other healthcare professional, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 31Mar2021 at 12:30 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included pain knee (reported as Chronic pain right knee) and factor v deficiency (reported as factor v).The patient previously had avocado and experienced fruit allergy to avocado. The patient had latex allergy. The patient previously had received antibiotics and experienced allergy to antibiotic. Concomitant medications taken within two weeks of vaccination included paracetamol, oxycodone hydrochloride (PERCOCET), buspirone (BUSPERONE) and escitalopram oxalate (LEXIPRO), all from unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 at 11:00, the patient started with lymphnodes, fever for five days, severe stomach bloating, and a rash from an unknown date in Apr2021. The events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the events. The clinical outcome of the event fever for five days was resolved on 05Apr2021. The clinical outcome of the events started with lymphnodes, severe stomach bloating, a rash was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal distension, Lymphadenopathy, Pyrexia, Rash
Clinical narrative: Started with lymphnodes, fever for 5 days, severe stomach bloating, now a rash; Started with lymphnodes, fever for 5 days, severe stomach bloating, now a rash; Started with lymphnodes, fever for 5 days, severe stomach bloating, now a rash; Started with lymphnodes, fever for 5 days, severe stomach bloating, now a rash; This is a spontaneous report from a contactable other healthcare professional, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 31Mar2021 at 12:30 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included pain knee (reported as Chronic pain right knee) and factor v deficiency (reported as factor v).The patient previously had avocado and experienced fruit allergy to avocado. The patient had latex allergy. The patient previously had received antibiotics and experienced allergy to antibiotic. Concomitant medications taken within two weeks of vaccination included paracetamol, oxycodone hydrochloride (PERCOCET), buspirone (BUSPERONE) and escitalopram oxalate (LEXIPRO), all from unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 at 11:00, the patient started with lymphnodes, fever for five days, severe stomach bloating, and a rash from an unknown date in Apr2021. The events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the events. The clinical outcome of the event fever for five days was resolved on 05Apr2021. The clinical outcome of the events started with lymphnodes, severe stomach bloating, a rash was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pruritus
Clinical narrative: Excessive sleepiness; All over low grade body itch; Sore arm; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 11Apr2021 at 14:45 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included acid reflux (esophageal), alopecia areata and allergy to walnuts and pecans. Concomitant medication included omeprazole (MANUFACTURER UNKNOWN) from an unknown date for an unspecified indication. The patient previously received amoxicillin (MANUFACTURER UNKNOWN) from an unknown date for an unspecified indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021 at 19:30, the patient experienced all over low-grade body itch, sore arm, excessive sleepiness. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events excessive sleepiness, all over low-grade body itch and sore arm was not resolved, at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypersomnia, Pain in extremity, Pruritus
Clinical narrative: Excessive sleepiness; All over low grade body itch; Sore arm; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 11Apr2021 at 14:45 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included acid reflux (esophageal), alopecia areata and allergy to walnuts and pecans. Concomitant medication included omeprazole (MANUFACTURER UNKNOWN) from an unknown date for an unspecified indication. The patient previously received amoxicillin (MANUFACTURER UNKNOWN) from an unknown date for an unspecified indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021 at 19:30, the patient experienced all over low-grade body itch, sore arm, excessive sleepiness. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events excessive sleepiness, all over low-grade body itch and sore arm was not resolved, at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood test, Chest discomfort, Electrocardiogram
Clinical narrative: Woke up Saturday with the sensation of heart tightening and contracting. Thought I was having a heart attack at first but it came and went, no pain, just tightening feeling.; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 09Apr2021 at 13:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included diet controlled diabetic. The patient had no known allergies to medications, food, or other products. Concomitant medication taken within two weeks of vaccination included desvenlafaxine (MANUFACTURER UNKNOWN) from unknown date for unknown indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP75347) via an unspecified route of administration in the left arm on 19Mar2021 at 12:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient woke up Saturday on 10Apr2021 at 06:00, with the sensation of heart tightening and contracting. Thought she was having a heart attack at first but it came and went, no pain, just tightening feeling. The event resulted in doctor or other healthcare professional office/clinic visit. The event resulted in emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. The clinical outcome of the event woke up Saturday with the sensation of heart tightening and contracting, thought was having a heart attack at first but it came and went, no pain, just tightening feeling was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chest discomfort
Clinical narrative: Woke up Saturday with the sensation of heart tightening and contracting. Thought I was having a heart attack at first but it came and went, no pain, just tightening feeling.; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 09Apr2021 at 13:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included diet controlled diabetic. The patient had no known allergies to medications, food, or other products. Concomitant medication taken within two weeks of vaccination included desvenlafaxine (MANUFACTURER UNKNOWN) from unknown date for unknown indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP75347) via an unspecified route of administration in the left arm on 19Mar2021 at 12:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient woke up Saturday on 10Apr2021 at 06:00, with the sensation of heart tightening and contracting. Thought she was having a heart attack at first but it came and went, no pain, just tightening feeling. The event resulted in doctor or other healthcare professional office/clinic visit. The event resulted in emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. The clinical outcome of the event woke up Saturday with the sensation of heart tightening and contracting, thought was having a heart attack at first but it came and went, no pain, just tightening feeling was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Rash
Clinical narrative: shingles; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730) via an unspecified route of administration in the right arm on 26Mar2021 at 11:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies. Concomitant medications included norethisterone acetate, ethinylestradiol, ferrous fumarate (BLISOVI 24 FE) taken for unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in the left arm on an unspecified date in Mar2021 at 11:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021, the patient started developing shingles around 10 days following the second dose of vaccine. The doctor thought her immune response to the vaccine triggered chicken pox cells in her system, resulting in shingles. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the event shingles which included treatment with VALTREX and prednisone. The clinical outcome of the event shingles was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Herpes zoster
Clinical narrative: shingles; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730) via an unspecified route of administration in the right arm on 26Mar2021 at 11:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies. Concomitant medications included norethisterone acetate, ethinylestradiol, ferrous fumarate (BLISOVI 24 FE) taken for unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route of administration in the left arm on an unspecified date in Mar2021 at 11:30 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021, the patient started developing shingles around 10 days following the second dose of vaccine. The doctor thought her immune response to the vaccine triggered chicken pox cells in her system, resulting in shingles. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the event shingles which included treatment with VALTREX and prednisone. The clinical outcome of the event shingles was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus; This is a spontaneous report from a contactable other healthcare professional, the patient. A 66-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3246) via an unspecified route of administration in the right arm on 08Jan2021 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included osteoporosis. Concomitant medications included ascorbic acid (VITAMIN C),calcium, colecalciferol (CALCIUM WITH D3) and fish oil (MANUFACTURER UNKNOWN). The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EJ1685) via an unspecified route of administration in the right arm on 18Dec2020 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. The patient previously also received BACTRIUM and experienced allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 28Jan2021, the patient experienced tinnitus. The event tinnitus was intermittent. The patient used to have a few days of no tinnitus and then a couple/a few days of tinnitus. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event tinnitus was not resolved.   No follow-up attempts are needed. No further information is expected.